ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 Shares of Company Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the transaction, the chief executive officer directly owned 333,689 shares of the company’s stock, valued at approximately $23,988,902.21. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.00, for a total value of $383,400.00.
• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.30, for a total value of $401,220.00.

ANI Pharmaceuticals Stock Up 0.0%

ANIP traded up $0.01 on Friday, hitting $72.29. The company had a trading volume of 333,921 shares, compared to its average volume of 412,460. The stock has a fifty day moving average price of $73.59 and a 200-day moving average price of $77.97. ANI Pharmaceuticals, Inc. has a 12-month low of $69.58 and a 12-month high of $97.00. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 15.58, a P/E/G ratio of 2.33 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the prior year, the firm posted $1.80 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Guggenheim reduced their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price on the stock. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $99.60.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $15,154,000. NFJ Investment Group LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at approximately $2,766,000. Walleye Capital LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at approximately $8,784,000. Jupiter Topco LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth $6,597,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth $1,449,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.